Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus FEMINONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus FEMINONE.
DIETHYLSTILBESTROL vs FEMINONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
FEMINONE (progesterone) is a steroid hormone that binds to the progesterone receptor, modulating gene expression in target tissues. It transforms the endometrium from proliferative to secretory phase, reduces endometrial hyperplasia risk, and suppresses gonadotropin release via negative feedback.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
0.625 mg orally once daily
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 7-8 hours (range 5-12 h); clinical significance: steady-state reaches after ~2-3 days, necessitates daily dosing for contraceptive efficacy.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Feminone (norethindrone) is primarily excreted in urine (approximately 70-80% as metabolites, with <5% as unchanged drug) and feces (20-30%).
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."